Phosphodiesterase 4 inhibitors for psoriatic arthritis

To evaluate the benefits and harms of PDE4 inhibitors (e.g., apremilast) for the treatment of PsA.

This is a protocol.

Health topics:

Published:

15 October 2016

Authors:

Zamora NV, Valerio-Morales I, Lopez-Olivo M, Pan X, Suarez-Almazor ME

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Zamora NV, Valerio-Morales I, Lopez-Olivo M, Pan X, Suarez-Almazor ME. Phosphodiesterase 4 inhibitors for psoriatic arthritis. Cochrane Database of Systematic Reviews 2016, Issue 10. Art. No.: CD012401. DOI: 10.1002/14651858.CD012401